Overview

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Status:
RECRUITING

Trial end date:
2028-02-01

Target enrollment:

Participant gender:

Summary

The current study is an investigator-initiated, single-arm phase 2 study that enrolled patients with recurrent and/or metastatic Ewing sarcoma for the treatment of Irinotecan Liposome (II) Combined with Temozolomide and Fluzoparib as the second-line treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Treatments:

fluzoparib
irinotecan sucrosofate
Temozolomide